Circulating Inflammation Markers, Risk of Lung Cancer, and Utility for Risk Stratification-Reference-Cited by-同舟云学术

Circulating Inflammation Markers, Risk of Lung Cancer, and Utility for Risk Stratification

Published:2015-07-28 Issue:10 Volume:107 Page:
ISSN:1460-2105
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Shiels Meredith S.¹,Katki Hormuzd A.¹,Hildesheim Allan¹,Pfeiffer Ruth M.¹,Engels Eric A.¹,Williams Marcus¹,Kemp Troy J.¹,Caporaso Neil E.¹,Pinto Ligia A.¹,Chaturvedi Anil K.¹

Affiliation:

1. Affiliations of authors: Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD (MSS, HAK, AH, RMP, EAE, NEC, AKC); HPV Immunology Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc, Frederick, MD (MW, TJK, LAP).

Funder

National Cancer Institute

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/107/10/djv199/25422252/djv199.pdf

Reference34 articles.

1. Inflammation, a key event in cancer development;Lu;Mol Cancer Res,2006

2. Inflammation and lung cancer: roles of reactive oxygen/nitrogen species;Azad;J Toxicol Environ Health B Crit Rev,2008

3. Chlamydia pneumoniae infection and risk for lung cancer;Chaturvedi;Cancer Epidemiol Biomarkers Prev,2010